Health News Review
  • Jan 24 2013

    “The risk that press reports would fall into the trap of reporting this study as definitive”

    A paper in JAMA Internal Medicine this week, “The Association of Aspirin Use With Age-Related Macular Degeneration,” concluded: “..from this prospective population-based cohort that regular aspirin use is associated with a 2-fold increase in risk of age-related macular degeneration (AMD) during a 15-year period. These findings appear to be independent of cardiovascular disease, smoking, and [...]

    No Comments
  • Jan 23 2013

    Introducing a three-part series on medical journal ghostwriting

    Today we publish part one of a three-part guest blog series that came to us in an unsolicited submission.  But because we’ve followed the two authors’ work, we are pleased to accept and pass along their thoughts.  Here is the first of the series by Jonathan Leo, PhD, and Jeffrey Lacasse, Ph.D. Part One: When Should [...]

    4 Comments
  • Nov 27 2012

    Heart journals ask scientist-authors to do what we’ve been teaching journalists for years

    For years we have been coaxing and educating journalists – and the general public – to understand that the language used to describe studies – especially observational studies – is important. We have published a primer, “Does the Language Fit the Evidence?  Association Versus Causation.” Well don’t feel picked on any longer, journalists.  Some journals [...]

    No Comments
  • Nov 5 2012

    “Embargoes… can be bad for the public health.”

    Let’s start the week with some embargo issues!  How’s that for fun? On the NPR Shots blog, David Schultz writes, “What We Wanted To Tell You About Mumps But Couldn’t.”   He begins: Last week, we wrote about an outbreak of mumps within several Orthodox Jewish communities in and around New York City. We told [...]

    No Comments
  • Nov 1 2012

    “Keep some healthy skepticism about claims for silver bullets, perfect cures, and huge effects”

    My enthusiasm for the work of Dr. John Ioannidis of Stanford is shared by Harold DeMonaco, one of our story reviewers on HealthNewsReview.org.  DeMonaco submitted the following guest blog post, which I’m pleased to publish: ——————————————— The headline of this post is a quote from a recent interview that Gary pointed to in a recent [...]

    4 Comments
  • Oct 31 2012

    Take that, Ingelfinger! Embargo Watch toasts new open-access journal’s policy

    On the Embargo Watch blog, Ivan Oransky writes: “eLife, the new open-access journal funded by the Howard Hughes Medical Institute, the Max Planck Society, and the Wellcome Trust, announced its media policy earlier this week.  … I love this policy. From the policy’s preamble: First, we are encouraging authors whose work has been accepted for [...]

    1 Comment
  • Oct 31 2012

    BMJ pushes Roche for raw data on Tamiflu trials

    BMJ journal editor Fiona Godlee this week published an open letter to Roche, makers of the flu drug Tamiflu. Background provided by BMJ: Roche promised in 2009 to release full reports from clinical trials of oseltamivir in response to an investigation by the BMJ and the Cochrane Collaboration. In this open letter to John Bell, [...]

    No Comments
  • Oct 25 2012

    Catching up on Embargo Watch & Retraction Watch gems

    On the Embargo Watch blog, Ivan Oransky keeps chipping away at the question of whose interests are served by embargoes. In “Break a JAMA embargo, get blacklisted.  Then what?” he writes: Adam Feuerstein and Patricia Anstett are part of an elite journalism club. They’ve both been blacklisted by the Journal of the American Medical Association [...]

    No Comments
  • Oct 10 2012

    HealthDay publishes two examples of news-release-journalism in one day

    And it may happen on many other days as well – with them – or with others.  But these two got our goat. 1.  New MRI MIght Help Spot Heart Disease Early:  Study It’s entirely based on a news release from the journal Radiology.  There is no independent analysis of claims such as this: “The [...]

    No Comments
  • Sep 24 2012

    More on publication bias and conflict of interest

    Recently, I wrote about an article published by PLoS One that pointed out the potential for flawed reporting on the results of published clinical trials. Now, Harold DeMonaco, one of our story reviewers and a frequent guest blogger on our site, writes about an article and accompanying editorial in the September 20 edition of the [...]

    2 Comments